I-Mab Appoints New Directors, Forms R&D Committee

I-Mab, a U.S.-based global biotech company specializing in precision immuno-oncology agents, announced key leadership changes to advance its strategic growth in cancer treatment. Effective August 22, 2025, Dr. Robert Lenz and Ms. Xin Liu were appointed as independent directors to the Board, with Dr. Lenz also chairing a newly formed Research and Development Committee designed to drive innovation. Dr. Sean Cao, an independent director since May 28, 2025, and CEO Dr. Sean Fu, join this committee. Lielie Zhang will step down from the Board, and Dr. Ken Takeshita has been added to the Scientific Advisory Board to further strengthen the company’s expertise. These leadership enhancements coincide with I-Mab’s focus on progressing givastomig, a bispecific antibody targeting Claudin 18.2-positive gastric cancers and other solid tumors. The company aims to leverage this strengthened governance to support R&D excellence and long-term innovation despite financial challenges noted by market analysts.